Despite regulatory challenges and global supply chain risks, the company proved stable and resilient. This performance continues the sustainable growth path of recent years, characterized by steady revenue increases, the expansion of in-house manufacturing capacities, and a growing global presence.

Chief Financial Officer Gerhard Mayer emphasizes:
“2025 was once again a year marked by exceptional challenges for our industry. Achieving strong growth under these conditions demonstrates the robustness of our strategic direction and the strength of our international structure.”
 

Investments in production capacity and supply reliability

Alongside revenue growth, Wörwag Pharma continued to invest in the expansion and modernization of its manufacturing sites: Wörwag Pharma Operations (WPO) in Łódź, Poland, and Wörwag Pharma Production (WPP) in Pöcking, Bavaria. Both sites have become integral components of the company’s international supply capabilities. The continuous expansion of in-house production strengthens global supply security.

At the same time, key supply chain processes are being harmonized to further improve efficiency and planning reliability.

 

Further strengthening market development and international presence

In 2025, Wörwag Pharma further expanded its international market activities. Consumer communication initiatives were strengthened in numerous markets, both digitally and through traditional media. Engagement with patients and healthcare professionals continues to be refined. At the same time, the field force was expanded in several regions, and cooperation with distribution partners and pharmacy chains was intensified.

Wörwag Pharma is increasingly aligning its activities with global health trends - particularly the steadily rising incidence of diabetes and its associated complications. This trend affects both established markets in Central and Eastern Europe, where Wörwag Pharma has long been strongly positioned, and regions where metabolic and neuropathic diseases are becoming a growing health challenge.

“We are strengthening our established markets while selectively leveraging opportunities in countries where medical demand is growing. This clear focus enables us to expand our presence step by step and achieve sustainable growth,” says Chief Executive Officer Jochen Schlindwein, commenting on the company’s international market strategy.

Portfolio: strong performance and successful new launches

The product portfolio also developed positively in 2025. B12 Ankermann achieved above-average growth in Germany, significantly increasing its presence in pharmacies and among patients.

Another highlight is Lagosa Triplex^®, which further expands the company’s expertise in metabolic health. Modern lifestyles - characterized by unbalanced diets and lack of physical activity - are placing increasing strain on metabolism, the cardiovascular system, and the liver. Against this backdrop, Wörwag Pharma focuses on scientifically substantiated solutions for the prevention and management of lifestyle-related diseases.
With the launch of Lagosa Triplex^®, planned in Germany for April 1, 2026, the company is setting an important strategic accent. The patent-pending combination of three natural ingredients supports the natural function of the heart, liver, and lipid metabolism. The formulation is based on current scientific findings and offers high bioavailability.

Lagosa Triplex^® strengthens Wörwag Pharma’s portfolio and underscores the company’s ambition to systematically combine medical expertise, research, and innovation.